1987, ISBN 9782906700000, 47
Book
Journal of Clinical Oncology, ISSN 0732-183X, 01/2008, Volume 26, Issue 3, pp. 440 - 446
Purpose High amounts of intratumoral macrophages have been shown to correlate with poor prognosis in patients with follicular lymphoma (FL) treated with...
SURVIVAL | CELLS | PREDICTS | MECHANISM | VIVO | ONCOLOGY | GENE-EXPRESSION | MONONUCLEAR PHAGOCYTES | Doxorubicin - therapeutic use | Lymphoma, Follicular - metabolism | Lymphoma, Follicular - drug therapy | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Cyclophosphamide - therapeutic use | Antigens, CD - metabolism | Teniposide - therapeutic use | Adult | Female | Antibodies, Monoclonal, Murine-Derived | Macrophages - pathology | Lymphoma, Follicular - pathology | Interferon-alpha - therapeutic use | Rituximab | Survival Rate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antigens, Differentiation, Myelomonocytic - metabolism | Aged | Prednisone - therapeutic use
SURVIVAL | CELLS | PREDICTS | MECHANISM | VIVO | ONCOLOGY | GENE-EXPRESSION | MONONUCLEAR PHAGOCYTES | Doxorubicin - therapeutic use | Lymphoma, Follicular - metabolism | Lymphoma, Follicular - drug therapy | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Cyclophosphamide - therapeutic use | Antigens, CD - metabolism | Teniposide - therapeutic use | Adult | Female | Antibodies, Monoclonal, Murine-Derived | Macrophages - pathology | Lymphoma, Follicular - pathology | Interferon-alpha - therapeutic use | Rituximab | Survival Rate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antigens, Differentiation, Myelomonocytic - metabolism | Aged | Prednisone - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 13, pp. 1287 - 1295
This study of the treatment of aggressive lymphoma in patients 60 years old or younger compared cyclophosphamide, doxorubicin, vincristine, and prednisone...
MEDICINE, GENERAL & INTERNAL | THERAPY | SURVIVAL BENEFIT | BONE-MARROW-TRANSPLANTATION | NON-HODGKINS-LYMPHOMA | CHOP | REMISSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Lymphoma - mortality | Stem Cell Transplantation | Lymphoma - drug therapy | Lymphoma - therapy | Melphalan - adverse effects | Vindesine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Methotrexate - adverse effects | Melphalan - administration & dosage | Adolescent | Survival Analysis | Vindesine - administration & dosage | Vincristine - adverse effects | Methotrexate - administration & dosage | Doxorubicin - adverse effects | Epirubicin - adverse effects | Bone marrow | Chemotherapy | Lymphomas | Transplants & implants
MEDICINE, GENERAL & INTERNAL | THERAPY | SURVIVAL BENEFIT | BONE-MARROW-TRANSPLANTATION | NON-HODGKINS-LYMPHOMA | CHOP | REMISSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Lymphoma - mortality | Stem Cell Transplantation | Lymphoma - drug therapy | Lymphoma - therapy | Melphalan - adverse effects | Vindesine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Methotrexate - adverse effects | Melphalan - administration & dosage | Adolescent | Survival Analysis | Vindesine - administration & dosage | Vincristine - adverse effects | Methotrexate - administration & dosage | Doxorubicin - adverse effects | Epirubicin - adverse effects | Bone marrow | Chemotherapy | Lymphomas | Transplants & implants
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1128 - 1135
Background We analyzed detailed characteristics and salvage treatment in 175 follicular lymphoma patients from the FL2000 study who were in progression after...
Follicular lymphoma | Rituximab | Autologous stem cell transplantation | MULTICENTER | follicular lymphoma | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | PROGRESSION-FREE SURVIVAL | autologous stem cell transplantation | CHEMOTHERAPY | TRIAL | INTERFERON | HIGH-DOSE THERAPY | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | HEMATOLOGY | rituximab | Recurrence | Lymphoma, Follicular - therapy | Age Factors | Lymphoma, Follicular - pathology | Humans | Middle Aged | Risk Factors | Salvage Therapy | Hematopoietic Stem Cell Transplantation | Lymphoma, Follicular - mortality | Male | Transplantation, Autologous | Treatment Outcome | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Disease Progression | Survival Analysis | Adult | Female | Aged | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Original
Follicular lymphoma | Rituximab | Autologous stem cell transplantation | MULTICENTER | follicular lymphoma | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | PROGRESSION-FREE SURVIVAL | autologous stem cell transplantation | CHEMOTHERAPY | TRIAL | INTERFERON | HIGH-DOSE THERAPY | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | HEMATOLOGY | rituximab | Recurrence | Lymphoma, Follicular - therapy | Age Factors | Lymphoma, Follicular - pathology | Humans | Middle Aged | Risk Factors | Salvage Therapy | Hematopoietic Stem Cell Transplantation | Lymphoma, Follicular - mortality | Male | Transplantation, Autologous | Treatment Outcome | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Disease Progression | Survival Analysis | Adult | Female | Aged | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Original
Journal Article
Human Pathology, ISSN 0046-8177, 2014, Volume 45, Issue 10, pp. 2085 - 2093
Summary Detection of MUM1+ cells in follicular lymphoma (FL) tissues was previously found to be associated with poor prognosis in a single report, whereas the...
Pathology | Immunohistochemistry | Follicular lymphoma | MUM1 | Ki-67 | Image analysis | Prognosis | YOUNG-ADULTS | PROTEIN | TRANSCRIPTION FACTOR IRF4 | QUANTIFICATION | PATHOLOGY | CHEMOTHERAPY | MICROENVIRONMENT | RITUXIMAB | DIFFERENTIATION | EXPRESSION | T-CELLS | Lymphoma, Follicular - metabolism | Lymphoma, Follicular - drug therapy | Biomarkers, Tumor - analysis | Humans | Middle Aged | Proportional Hazards Models | Lymphoma, Follicular - mortality | Male | Young Adult | Disease-Free Survival | Ki-67 Antigen - analysis | Image Processing, Computer-Assisted | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Interferon Regulatory Factors - biosynthesis | Adult | Female | Ki-67 Antigen - biosynthesis | Aged | Interferon Regulatory Factors - analysis | Lymphomas | Equipment and supplies | Image processing | Analysis | Confidence intervals | Automation | Biopsy | Medical treatment | Medical prognosis | Multivariate analysis | Life Sciences
Pathology | Immunohistochemistry | Follicular lymphoma | MUM1 | Ki-67 | Image analysis | Prognosis | YOUNG-ADULTS | PROTEIN | TRANSCRIPTION FACTOR IRF4 | QUANTIFICATION | PATHOLOGY | CHEMOTHERAPY | MICROENVIRONMENT | RITUXIMAB | DIFFERENTIATION | EXPRESSION | T-CELLS | Lymphoma, Follicular - metabolism | Lymphoma, Follicular - drug therapy | Biomarkers, Tumor - analysis | Humans | Middle Aged | Proportional Hazards Models | Lymphoma, Follicular - mortality | Male | Young Adult | Disease-Free Survival | Ki-67 Antigen - analysis | Image Processing, Computer-Assisted | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Interferon Regulatory Factors - biosynthesis | Adult | Female | Ki-67 Antigen - biosynthesis | Aged | Interferon Regulatory Factors - analysis | Lymphomas | Equipment and supplies | Image processing | Analysis | Confidence intervals | Automation | Biopsy | Medical treatment | Medical prognosis | Multivariate analysis | Life Sciences
Journal Article
Haematologica, ISSN 0390-6078, 07/2013, Volume 98, Issue 7, pp. 1107 - 1114
Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follicular lymphoma needing cytotoxic therapy. Four randomized...
UNITED-STATES | PREDNISONE | THERAPY | CYCLOPHOSPHAMIDE | PHASE-III | VINCRISTINE | DOXORUBICIN | IMPROVED SURVIVAL | HEMATOLOGY | CHEMOTHERAPY | DETUDE DES LYMPHOMES | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - mortality | Rituximab | Male | Teniposide - administration & dosage | Interferon-alpha - administration & dosage | Young Adult | Time Factors | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Cohort Studies | Doxorubicin - administration & dosage | Index Medicus | Life Sciences | Human health and pathology | Immunology | Hematology | Immunotherapy | Cancer | Original and Brief Reports
UNITED-STATES | PREDNISONE | THERAPY | CYCLOPHOSPHAMIDE | PHASE-III | VINCRISTINE | DOXORUBICIN | IMPROVED SURVIVAL | HEMATOLOGY | CHEMOTHERAPY | DETUDE DES LYMPHOMES | Cyclophosphamide - administration & dosage | Prednisone - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Lymphoma, Follicular - mortality | Rituximab | Male | Teniposide - administration & dosage | Interferon-alpha - administration & dosage | Young Adult | Time Factors | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Cohort Studies | Doxorubicin - administration & dosage | Index Medicus | Life Sciences | Human health and pathology | Immunology | Hematology | Immunotherapy | Cancer | Original and Brief Reports
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1530 - 1542
Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line...
FDG-PET | CRITERIA | FONDAZIONE ITALIANA LINFOMI | SUBSET ANALYSIS | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | THERAPY | ONCOLOGY | PROGRESSION-FREE SURVIVAL | FOLL05 TRIAL | MINIMAL RESIDUAL DISEASE | Pets | Lymphomas | Prognosis | Analysis
FDG-PET | CRITERIA | FONDAZIONE ITALIANA LINFOMI | SUBSET ANALYSIS | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | THERAPY | ONCOLOGY | PROGRESSION-FREE SURVIVAL | FOLL05 TRIAL | MINIMAL RESIDUAL DISEASE | Pets | Lymphomas | Prognosis | Analysis
Journal Article
Blood, ISSN 0006-4971, 12/2008, Volume 112, Issue 13, pp. 4824 - 4831
The FL2000 study was undertaken to evaluate the combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy plus interferon in the first-line...
TRIAL | ANTI-CD20 MONOCLONAL-ANTIBODY | B-CELL | HIGH-DOSE THERAPY | COMBINATION IMMUNOTHERAPY | NON-HODGKINS-LYMPHOMA | LOW-GRADE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MAINTENANCE THERAPY | DETUDE DES LYMPHOMES | Antibodies, Monoclonal, Murine-Derived | Lymphoma, Follicular - drug therapy | Prognosis | Humans | Lymphoma, Follicular - diagnosis | Etoposide | Lymphoma, Follicular - mortality | Rituximab | Treatment Outcome | Recombinant Proteins | Doxorubicin | Interferon-alpha - administration & dosage | Cyclophosphamide | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Prednisolone | Index Medicus | Abridged Index Medicus
TRIAL | ANTI-CD20 MONOCLONAL-ANTIBODY | B-CELL | HIGH-DOSE THERAPY | COMBINATION IMMUNOTHERAPY | NON-HODGKINS-LYMPHOMA | LOW-GRADE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MAINTENANCE THERAPY | DETUDE DES LYMPHOMES | Antibodies, Monoclonal, Murine-Derived | Lymphoma, Follicular - drug therapy | Prognosis | Humans | Lymphoma, Follicular - diagnosis | Etoposide | Lymphoma, Follicular - mortality | Rituximab | Treatment Outcome | Recombinant Proteins | Doxorubicin | Interferon-alpha - administration & dosage | Cyclophosphamide | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Prednisolone | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 822 - 829
Purpose First-line treatment for patients with newly diagnosed follicular lymphoma (FL) still remains debated, even in the rituximab-based combination therapy...
FRONT-LINE | INTERFERON | ONCOLOGY | HIGH-DOSE THERAPY | RITUXIMAB | DOXORUBICIN | NON-HODGKINS-LYMPHOMA | RANDOMIZED-TRIAL | CHOP | STEM-CELL TRANSPLANTATION | CHEMOTHERAPY | Recurrence | Lymphoma, Follicular - drug therapy | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Agents - administration & dosage | Patient Selection | Young Adult | Time Factors | Adult | France | Antibodies, Monoclonal, Murine-Derived | Risk Assessment | Lymphoma, Follicular - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Lymphoma, Follicular - mortality | Rituximab | Treatment Outcome | Remission Induction | Belgium | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Neoplasm Staging | Life Sciences | Immunology
FRONT-LINE | INTERFERON | ONCOLOGY | HIGH-DOSE THERAPY | RITUXIMAB | DOXORUBICIN | NON-HODGKINS-LYMPHOMA | RANDOMIZED-TRIAL | CHOP | STEM-CELL TRANSPLANTATION | CHEMOTHERAPY | Recurrence | Lymphoma, Follicular - drug therapy | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Agents - administration & dosage | Patient Selection | Young Adult | Time Factors | Adult | France | Antibodies, Monoclonal, Murine-Derived | Risk Assessment | Lymphoma, Follicular - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Lymphoma, Follicular - mortality | Rituximab | Treatment Outcome | Remission Induction | Belgium | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Neoplasm Staging | Life Sciences | Immunology
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2812 - 2812
Introduction: Most patients with newly diagnosed FL treated with rituximab (R) alone or R + chemotherapy will experience prolonged progression-free survival...
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2010, Volume 151, Issue 2, pp. 159 - 166
Summary Peripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than...
cyclophosphamide | clinical trials | vincristine | doxorubicin | prednisone (CHOP) | T‐cell lymphoma | T-cell lymphoma | CLASSIFICATION | IFOSFAMIDE | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | PREDNISONE | THERAPY | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Ifosfamide - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Adolescent | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Anthracyclines | Cyclophosphamide | Corticosteroids | Etoposide | Clinical trials | Product development | Prednisone | Non-Hodgkin's lymphomas | T cells | double prime B-cell lymphoma | Cell survival | Vinblastine | Ifosfamide | Toxicity | Doxorubicin | Survival | Vincristine | Cisplatin | Dacarbazine | Bleomycin | Remission | double prime T-cell lymphoma | Anaplastic large-cell lymphoma | expressed sequence tags
cyclophosphamide | clinical trials | vincristine | doxorubicin | prednisone (CHOP) | T‐cell lymphoma | T-cell lymphoma | CLASSIFICATION | IFOSFAMIDE | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | PREDNISONE | THERAPY | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Ifosfamide - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Adolescent | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Anthracyclines | Cyclophosphamide | Corticosteroids | Etoposide | Clinical trials | Product development | Prednisone | Non-Hodgkin's lymphomas | T cells | double prime B-cell lymphoma | Cell survival | Vinblastine | Ifosfamide | Toxicity | Doxorubicin | Survival | Vincristine | Cisplatin | Dacarbazine | Bleomycin | Remission | double prime T-cell lymphoma | Anaplastic large-cell lymphoma | expressed sequence tags
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e20523 - e20523
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue 9, pp. 2380 - 2385
The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL). Of...
Follicular lymphoma | Rituximab | Low-burden | Induction monotherapy | induction monotherapy | CD20 EXPRESSION | follicular lymphoma | low-burden | MONOCLONAL-ANTIBODY | B-CELLS | ADVANCED-STAGE | PHASE-II TRIAL | POLICY | THERAPY | ONCOLOGY | ANTI-CD20 | NON-HODGKINS-LYMPHOMA | rituximab | Lymphoma, Follicular - drug therapy | Follow-Up Studies | Lymphoma, Follicular - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Lymphoma, Follicular - mortality | Induction Chemotherapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Disease-Free Survival | Immunization, Passive | Adult | Female | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Antibodies, Monoclonal, Murine-Derived | Antineoplastic Agents | Life Sciences | Immunology | Lymphoma, Follicular
Follicular lymphoma | Rituximab | Low-burden | Induction monotherapy | induction monotherapy | CD20 EXPRESSION | follicular lymphoma | low-burden | MONOCLONAL-ANTIBODY | B-CELLS | ADVANCED-STAGE | PHASE-II TRIAL | POLICY | THERAPY | ONCOLOGY | ANTI-CD20 | NON-HODGKINS-LYMPHOMA | rituximab | Lymphoma, Follicular - drug therapy | Follow-Up Studies | Lymphoma, Follicular - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Lymphoma, Follicular - mortality | Induction Chemotherapy | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Disease-Free Survival | Immunization, Passive | Adult | Female | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Antibodies, Monoclonal, Murine-Derived | Antineoplastic Agents | Life Sciences | Immunology | Lymphoma, Follicular
Journal Article
Blood, ISSN 0006-4971, 01/2009, Volume 113, Issue 5, pp. 995 - 1001
Autologous stem cell transplantation (ASCT) as first-line therapy for follicular lymphoma (FL) remains controversial. The multicenter study randomized 172...
TRIAL | LOW-GRADE LYMPHOMA | TUMOR BURDEN | BONE-MARROW-TRANSPLANTATION | PROGRESSION-FREE SURVIVAL | PLUS RITUXIMAB | NON-HODGKINS-LYMPHOMAS | MYELOABLATIVE THERAPY | MOLECULAR EVALUATION | HEMATOLOGY | DETUDE DES LYMPHOMES | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Lymphoma, Follicular - therapy | Follow-Up Studies | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Neoplasms, Second Primary - mortality | Survival Rate | Transplantation, Autologous | Stem Cell Transplantation | Bone Marrow Purging | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Adult | Female | Transplantation Conditioning | Index Medicus | Abridged Index Medicus | Myeloablative Agonists | Life Sciences | Cyclophosphamide | Immunology | Neoplasms, Second Primary | Immunotherapy | Lymphoma, Follicular
TRIAL | LOW-GRADE LYMPHOMA | TUMOR BURDEN | BONE-MARROW-TRANSPLANTATION | PROGRESSION-FREE SURVIVAL | PLUS RITUXIMAB | NON-HODGKINS-LYMPHOMAS | MYELOABLATIVE THERAPY | MOLECULAR EVALUATION | HEMATOLOGY | DETUDE DES LYMPHOMES | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Lymphoma, Follicular - therapy | Follow-Up Studies | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Neoplasms, Second Primary - mortality | Survival Rate | Transplantation, Autologous | Stem Cell Transplantation | Bone Marrow Purging | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Adult | Female | Transplantation Conditioning | Index Medicus | Abridged Index Medicus | Myeloablative Agonists | Life Sciences | Cyclophosphamide | Immunology | Neoplasms, Second Primary | Immunotherapy | Lymphoma, Follicular
Journal Article
Human Pathology, ISSN 0046-8177, 2008, Volume 39, Issue 2, pp. 194 - 200
Summary Rituximab, an anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphoma. Some reports have outlined histologic modifications in...
Pathology | Anti-CD20 monoclonal antibodies | Bone marrow | Follicular lymphoma | Bcl2 | T-cell infiltration | CD20 | APOPTOSIS | follicular lymphoma | bcl2 | ANTIBODY | MECHANISMS | PATHOLOGY | bone marrow | ANTI-CD20 | anti-CD20 monoclonal antibodies | NON-HODGKIN-LYMPHOMA | EXPRESSION | Translocation, Genetic | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Lymphoma, B-Cell - genetics | Lymphoma, Follicular - genetics | Adult | Female | DNA, Neoplasm - analysis | T-Lymphocytes - pathology | Lymphoma, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived | Lymphoma, B-Cell - mortality | Lymphoma, Follicular - pathology | Lymphoma, Follicular - mortality | Rituximab | Survival Rate | Treatment Outcome | Reverse Transcriptase Polymerase Chain Reaction | Chromosomes, Human, Pair 18 | Bone Marrow - pathology | Gene Rearrangement | Lymphoma, B-Cell - pathology | Chromosomes, Human, Pair 14 | Aged | Proto-Oncogene Proteins c-bcl-2 - genetics | Antimitotic agents | Care and treatment | Lymphomas | T cells | Antineoplastic agents | Health aspects | Cancer | Histology | Genes | Binding sites | T-Lymphocytes | Antineoplastic Agents | Antibodies, Monoclonal | Lymphoma, B-Cell | Life Sciences | Human health and pathology | DNA, Neoplasm | Lymphoma, Follicular | Proto-Oncogene Proteins c-bcl-2 | Bone Marrow
Pathology | Anti-CD20 monoclonal antibodies | Bone marrow | Follicular lymphoma | Bcl2 | T-cell infiltration | CD20 | APOPTOSIS | follicular lymphoma | bcl2 | ANTIBODY | MECHANISMS | PATHOLOGY | bone marrow | ANTI-CD20 | anti-CD20 monoclonal antibodies | NON-HODGKIN-LYMPHOMA | EXPRESSION | Translocation, Genetic | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Lymphoma, B-Cell - genetics | Lymphoma, Follicular - genetics | Adult | Female | DNA, Neoplasm - analysis | T-Lymphocytes - pathology | Lymphoma, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived | Lymphoma, B-Cell - mortality | Lymphoma, Follicular - pathology | Lymphoma, Follicular - mortality | Rituximab | Survival Rate | Treatment Outcome | Reverse Transcriptase Polymerase Chain Reaction | Chromosomes, Human, Pair 18 | Bone Marrow - pathology | Gene Rearrangement | Lymphoma, B-Cell - pathology | Chromosomes, Human, Pair 14 | Aged | Proto-Oncogene Proteins c-bcl-2 - genetics | Antimitotic agents | Care and treatment | Lymphomas | T cells | Antineoplastic agents | Health aspects | Cancer | Histology | Genes | Binding sites | T-Lymphocytes | Antineoplastic Agents | Antibodies, Monoclonal | Lymphoma, B-Cell | Life Sciences | Human health and pathology | DNA, Neoplasm | Lymphoma, Follicular | Proto-Oncogene Proteins c-bcl-2 | Bone Marrow
Journal Article